Navigation de collection par Sujet A few cases of thrombocytopenia and APS-like thrombotic events have been reported in recipients of adenoviral vector-based COVID-19 vaccines. However, the association of aPL with COVID-19 vaccination is unclear. In our study, the comparison between the 03 groups: COVID-19 patients (n=106), vaccine receivers (n=38) and healthy controls (n=70), showed aPL rates at : 40%, 84 % and 19% respectively. We found highly significant values of aPL levels: in COVID-19 patients vs healthy controls (p=0.005/OR=2.88), vaccine receivers vs healthy controls (p=10-10 /OR=18.63), vaccine receivers vs COVID-19 patients (p=10-5/OR=6.48). COVID-19 patients showed statistically significant values in anti-B2GP1 IgM positivity compared to vaccine receivers and healthy controls (p=0.004, p=0.015 respectively). While vaccine receivers showed very highly statistically significant values in aCL IgM positivity compared to COVID-19 patients and healthy controls (p=10-9, p=10-12 respectively). These considerations suggest that aPL may represent a risk factor for thrombotic events after COVID-19 vaccination and warrant further investigations.

Sauter vers : 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ou entrer les premières lettres :  
Montrant les résultats 1 à 1 de 1
Date de publicationTitreAuteur(s)
2022Les anticorps anti phospholipides chez les sujets vaccinés contre la COVID-19KERRACHE, Hamza; ZAROUTA, Mohamed Yacine; FLITI, Mohamed Oualid; BOUDJELLA., ML.(Promoteur)